Peptides
Peptide database
By goal Fat lossMuscle growthHealing and recoveryLongevityCognition and moodSkin and hairSexual healthImmunity and gut
Guides All guides What are peptides?Legal status in the USPharma vs compounded vs researchHow to read a COAReconstitution and storageMembersThe complete GLP-1 guideSide effects and red flagsHow to read peptide research
Tools All tools Reconstitution calculatorMembersMeasurement converterMembersHalf-life visualizerCompare peptidesPeptide finderGLP-1 titration viewerMembers
Topics
Sleep & Recovery Energy & Vitality Focus & Mind Strength & Performance Longevity & Aging Beauty & Skin Hormones & Metabolism Gut & Immunity
Resources
Peptide Database Peptide Tools Peptide Guides Lab Reader Compound Database Wearables & Devices Calculators Glossary
Newsletter Members: log in or create a free account Join free
Peptide tools

Find the peptides studied for your goal

Choose a goal and an evidence bar. You get a ranked list with the reasons each peptide is on it, approved medicines first. Of the 52 compounds in the database, 17 have an approved product somewhere and 12 have only animal or cell data.

1What do you want to read about?
2How strong does the evidence need to be?
Fat loss

16 compounds in the database are studied for fat loss. 4 have an approved product, 9 more have human data, and 3 rest on animal or cell work alone.

13shown
Approved medicinesTested in people, not approvedAnimal or cell data only

Approved medicines

An approved product exists, made under drug manufacturing rules and prescribed by a clinician. Check the indication: it may not be this goal.

  1. 01
    SemaglutideFDA-approvedA

    A once-weekly GLP-1 receptor agonist approved for type 2 diabetes, obesity, heart risk, kidney disease and fatty liver disease.

    • FDA-approved product: Ozempic for type 2 diabetes glycemic control; Rybelsus for type 2 diabetes glycemic control; Wegovy for chronic weight management in adults (children 12 and older...; Wegovy tablets for chronic weight management and cardiovascular risk reduction.
    • Evidence grade A: approved drug or multiple human RCTs.
    • About 300 published human studies.
    • Fat loss is the main thing it has been studied for.
    GLP-1 / incretin agonistRead the evidence
  2. 02
    TirzepatideFDA-approvedA

    A once-weekly GIP and GLP-1 dual agonist approved for type 2 diabetes, heart risk in diabetes, obesity and sleep apnea.

    • FDA-approved product: Mounjaro for type 2 diabetes glycemic control (adults; later extended to...; Zepbound for chronic weight management in adults with obesity, or....
    • Evidence grade A: approved drug or multiple human RCTs.
    • About 150 published human studies.
    • Fat loss is the main thing it has been studied for.
    GLP-1 / incretin agonistRead the evidence
  3. 03
    TesamorelinFDA-approvedA

    An FDA-approved GHRH analog that shrinks visceral belly fat in people with HIV lipodystrophy. Not approved for weight loss.

    • FDA-approved product: Egrifta for reduction of excess abdominal fat in HIV-infected adults....
    • Evidence grade A: approved drug or multiple human RCTs.
    • About 30 published human studies.
    • Fat loss is the main thing it has been studied for.
    • Banned in tested sport (WADA prohibited list).
    GHRH analogRead the evidence
  4. 04
    MazdutideApproved outside USA

    Weekly GLP-1 and glucagon dual agonist, approved in China in 2025 for weight management and type 2 diabetes; not approved in the US.

    • Approved outside the US: Xinermei (China (NMPA)) for long-term weight management in adults with BMI 28 or higher,....
    • Evidence grade A: approved drug or multiple human RCTs.
    • About 14 published human studies.
    • Fat loss is the main thing it has been studied for.
    GLP-1 / incretin agonistRead the evidence

Tested in people, not approved

Human studies exist, but no regulator has approved a product. Quality and safety of what is sold online are unverified.

  1. 05
    RetatrutideIn clinical trialsA

    An investigational once-weekly GIP, GLP-1 and glucagon triple agonist from Eli Lilly, in late phase 3 for obesity. Not approved.

    • Evidence grade A: approved drug or multiple human RCTs.
    • About 12 published human studies.
    • Fat loss is the main thing it has been studied for.
    • Still in clinical trials. Not approved anywhere.
    • Banned in tested sport (WADA prohibited list).
    GLP-1 / incretin agonistRead the evidence
  2. 06
    SurvodutideIn clinical trialsA

    Investigational weekly injection that hits glucagon and GLP-1 receptors, studied for obesity and fatty liver disease (MASH).

    • Evidence grade A: approved drug or multiple human RCTs.
    • About 12 published human studies.
    • Fat loss is the main thing it has been studied for.
    • Still in clinical trials. Not approved anywhere.
    • Banned in tested sport (WADA prohibited list).
    GLP-1 / incretin agonistRead the evidence
  3. 07
    CagrilintideIn clinical trialsB

    An investigational once-weekly amylin analog from Novo Nordisk, studied alone and with semaglutide as CagriSema. Not approved.

    • Evidence grade B: at least one human randomized trial.
    • About 12 published human studies.
    • Fat loss is the main thing it has been studied for.
    • Still in clinical trials. Not approved anywhere.
    • Banned in tested sport (WADA prohibited list).
    Amylin analogRead the evidence
  4. 08
    AOD-9604Research chemicalB

    16-amino-acid growth hormone fragment developed as an obesity pill; it failed its 536-person trial in 2007 and was never approved.

    • Evidence grade B: at least one human randomized trial.
    • About 6 published human studies.
    • Fat loss is the main thing it has been studied for.
    • Research chemical. Not approved for human use anywhere.
    • Banned in tested sport (WADA prohibited list).
    Metabolic (other)Read the evidence
  5. 09
    HGH Fragment 176-191Research chemicalB

    A 16-amino-acid piece of the tail of human growth hormone, tested as a fat-loss drug. Its human trials found no significant weight loss.

    • Evidence grade B: at least one human randomized trial.
    • About 6 published human studies.
    • Fat loss is the main thing it has been studied for.
    • Research chemical. Not approved for human use anywhere.
    • Banned in tested sport (WADA prohibited list).
    Metabolic (other)Read the evidence
  6. 10
    EloralintideIn clinical trialsB

    Lilly's investigational weekly amylin-receptor agonist; up to 20% weight loss at 48 weeks in phase 2, now in phase 3.

    • Evidence grade B: at least one human randomized trial.
    • About 4 published human studies.
    • Fat loss is the main thing it has been studied for.
    • Still in clinical trials. Not approved anywhere.
    • Banned in tested sport (WADA prohibited list).
    Amylin analogRead the evidence
  7. 11
    CJC-1295Research chemicalB

    A lab-modified version of the hormone that tells the pituitary to release growth hormone. Never approved; human data stop at dosing studies.

    • Evidence grade B: at least one human randomized trial.
    • About 3 published human studies.
    • Studied for fat loss, but that is not its main research focus.
    • Research chemical. Not approved for human use anywhere.
    • Banned in tested sport (WADA prohibited list).
    GHRH analogRead the evidence
  8. 12
    IpamorelinResearch chemicalB

    A five-amino-acid ghrelin-receptor agonist that releases growth hormone. Its only efficacy trial, for post-surgery gut paralysis, failed.

    • Evidence grade B: at least one human randomized trial.
    • About 2 published human studies.
    • Studied for fat loss, but that is not its main research focus.
    • Research chemical. Not approved for human use anywhere.
    • Banned in tested sport (WADA prohibited list).
    GH secretagogueRead the evidence
  9. 13
    SermorelinWithdrawnB

    The active 29-amino-acid piece of growth hormone-releasing hormone. FDA-approved for children until its maker stopped selling it in 2008.

    • Evidence grade B: at least one human randomized trial.
    • About 40 published human studies.
    • Studied for fat loss, but that is not its main research focus.
    • Was approved once, since withdrawn or discontinued.
    • Banned in tested sport (WADA prohibited list).
    GHRH analogRead the evidence
3 more compounds are hidden by your evidence threshold.
See the full fat loss goal page, with trial endpoints and mechanisms
How the ranking works

Four rules, in this order

  1. 1

    Match the goal

    Every peptide record lists the goals it has been studied for, most relevant first. The finder keeps the ones that match your goal, including those where it is a side interest.

  2. 2

    Apply your evidence bar

    "Approved only" keeps molecules sold as an approved medicine somewhere. "Human evidence" adds anything tested in people. "Include animal-only" adds the rest.

  3. 3

    Put approved medicines first

    Approved products always rank above unapproved ones, even when the unapproved one has a bigger trial. An approved product has passed manufacturing inspection and has a label with known side effects.

  4. 4

    Then rank on evidence

    Within each group, stronger evidence grade comes first, then peptides where your goal is the main research focus, then the number of human studies.

Include animal-only 52 compounds Human evidence 40 Approved 17
Each evidence bar narrows the database. Counts are for every goal combined.
By goal

How much of each goal rests on human data

Each bar is every compound studied for that goal, split by the strongest evidence behind it. Tap a goal for its full page.

Fat loss 4 9 3 16 Muscle growth 3 7 6 16 Healing and recovery 1 7 3 11 Longevity 5 8 3 16 Cognition and mood 7 7 3 17 Skin and hair 1 3 2 6 Sexual health 5 2 7 Immunity and gut 3 5 1 9
Approved product Human data, not approved Animal or cell only
The Staate peptide brief

Know when a peptide moves up a grade

One email when a new human trial is published, a label changes or the FDA acts on a peptide. We say what the result means and link the source.
Frequently asked questions
What is the best peptide for weight loss?
The peptides with the largest human trials for weight loss are the approved GLP-1 drugs: semaglutide (Wegovy) and tirzepatide (Zepbound). In their main trials, average weight loss was about 15% of body weight on semaglutide over 68 weeks and about 21% on the highest tirzepatide dose over 72 weeks. Retatrutide has larger losses in trials but is not approved. A clinician can tell you whether any of them suits you.
Why does the finder put approved drugs first even when they are not approved for my goal?
Because an approved product is made to a known standard and its side effects are documented on a label. That is a different level of certainty than a research chemical of unknown purity. Each result says what the approval is for, so you can see when it is a different condition.
What does "research chemical" mean?
It means the peptide is sold labeled "for research use only, not for human consumption". It has not been approved for human use anywhere, and nothing checks that the vial contains what the label says. Many of the most discussed peptides, including BPC-157 and TB-500, are only available this way in the US.
Is a peptide with animal data only worth anything?
It shows a mechanism worth testing. It does not show that the peptide works or is safe in people. Most results in rodents fail to repeat in human trials, which is why the finder hides animal-only peptides unless you ask for them.
Does the finder recommend a peptide or a dose?
No. It sorts the published research so you can see what has been tested and how well. It never suggests a dose. Treatment decisions belong with a clinician who knows your history.
Sources
  1. Wilding JPH et al. (2021). Once-weekly semaglutide in adults with overweight or obesity (STEP 1). NEJM 384:989-1002.
  2. Jastreboff AM et al. (2022). Tirzepatide once weekly for the treatment of obesity (SURMOUNT-1). NEJM 387:205-216.
  3. U.S. FDA. Drugs@FDA: FDA-approved drug products database.
  4. U.S. FDA. Certain bulk drug substances for use in compounding that may present significant safety risks.
  5. World Anti-Doping Agency. The Prohibited List.
  6. Seyhan AA (2019). Lost in translation: the valley of death across preclinical and clinical divide. Translational Medicine Communications 4:18.

This is educational information, not medical advice. Talk to a qualified healthcare professional before changing your treatment, medication, or supplement routine, especially if you are pregnant, nursing, or managing a health condition.